Esketamine for depression: all studies (page 38)

Heart Rate Variability as a Potential Predictor of Response to Intranasal Esketamine in Patients with Treatment-Resistant Depression: A Preliminary Report.

Journal of Clinical Medicine August 14, 2024 Lorenzo Moccia, Giovanni Bartolucci, Maria Pepe et al. 7 citations

Background: Esketamine has received approval as a nasal spray (ESK-NS) for treatment-resistant depression (TRD) and evidence from real-world investigations has confirmed the effectiveness of ESK-NS, albeit with interindividual differences in response. Heart rate variability (HRV), defined as the fluctuation in time interval between consecutive heartbeats, can be used to measure autonomic...

DOI: 10.3390/jcm13164767 Full text Esketamine Mood disorders Personalized medicine Mental-health +4

Low dose of esketamine after childbirth helps mothers at risk of depression

The Brown University Psychopharmacology Update August 1, 2024

Women with prenatal depressive symptoms who received a single low dose of esketamine shortly after childbirth showed a substantially lower incidence of a major depressive episode at 42 days postpartum than women receiving placebo, a new study has found. Neuropsychiatric adverse events occurred more frequently in the esketamine group, but no severe adverse events were reported.

DOI: 10.1002/pu.31189

Rapid and long-lasting effects of subcutaneous esketamine on suicidality: An open-label study in patients with treatment-resistant depression.

Journal of Psychiatric Research August 1, 2024 Eduardo Igor Torquato Cardoso Lopes, Patrícia Cavalcanti-Ribeiro, Fernanda Palhano-Fontes et al. 9 citations

Therapeutics for suicide management is limited, taking weeks to work. This open-label clinical trial with 18 treatment-resistant depressive patients tested subcutaneous esketamine (8 weekly sessions) for suicidality. We noted a rapid and enduring effect of subcutaneous esketamine, lasting from one week to six months post-treatment, assessed by the Beck Inventory for Suicidality (BSI). There was...

DOI: 10.1016/j.jpsychires.2024.06.020 Full text Treatment-resistant depression Mental health treatment Suicide prevention Esketamine therapy +2

Safety and tolerability of esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression.

European Neuropsychopharmacology August 1, 2024 Roger S McIntyre, Istvan Bitter, Jozefien Buyze et al. 30 citations

In ESCAPE-TRD (NCT04338321), esketamine nasal spray (NS) significantly increased the probability of remission at Week 8, and of being relapse-free through Week 32 after remission at Week 8, versus quetiapine extended release (XR) in patients with treatment resistant depression (TRD). Here, we explore the time course, burden and consequences of treatment emergent adverse events (TEAEs) in the...

DOI: 10.1016/j.euroneuro.2024.05.009 Full text Major depressive disorder Treatment-resistant depression Drug tolerability Quetiapine +5

The Resistant Depression Response to Esketamine Assessing Metabolomics (ReDREAM) Project-Untargeted Metabolomics to Identify Biomarkers of Treatment Response to Intranasal Esketamine in Individuals with Treatment-Resistant Depression: A Study Protocol.

Alpha psychiatry August 1, 2024 Francesco Bartoli, Daniele Cavaleri, Ilaria Riboldi et al. 4 citations

Treatment-resistant depression (TRD) affects around 20-30% of people with major depressive disorder. In 2019, esketamine nasal spray was approved for TRD by both the US Food and Drug Administration and the European Medicines Agency. While its clinical efficacy and safety are proven, the mechanisms underlying its antidepressant effect remain unclear. The use of metabolomics may allow...

DOI: 10.5152/alphapsychiatry.2024.241549 Full text Esketamine Major depressive disorder Mdd Biomarkers biological markers +6

Long-term follow-up of participants in ketamine clinical trials for mood disorders.

Journal of Affective Disorders July 15, 2024 Kelly T Hurst, Abigail Vogeley, Deanna K Greenstein et al. 8 citations

Participants who received ketamine at the NIMH were among the first to receive ketamine for depression in controlled clinical trials, providing a unique opportunity to assess long-term outcomes. This analysis evaluated the relationship between participating in a ketamine clinical trial and subsequent ketamine/esketamine use after leaving the research setting. Participants seen within the NIMH...

DOI: 10.1016/j.jad.2024.04.062 Full text Esketamine Clinical trials Clinical-trials Depression-treatment +3

Esketamine in depression: putative biomarkers from clinical research.

European Archives of Psychiatry and Clinical Neuroscience July 13, 2024 Jenessa N Johnston, Carlos A. Zarate, Mark D Kvarta 18 citations

The discovery of racemic (R, S)-ketamine as a rapid-acting antidepressant and the subsequent FDA approval of its (S)-enantiomer, esketamine, for treatment-resistant depression (TRD) are significant advances in the development of novel neuropsychiatric therapeutics. Esketamine is now recognized as a powerful tool for addressing persistent symptoms of TRD compared to traditional oral...

DOI: 10.1007/s00406-024-01865-1 Full text Spravato Mechanism of action Suicide Treatment-resistant depression trd +6

Efficacy of intravenous ketamine and intranasal esketamine with dose escalation for Major depression: A systematic review and meta-analysis.

Journal of Affective Disorders July 1, 2024 Ashok Seshadri, Larry J. Prokop, Balwinder Singh 50 citations

Intravenous (IV) racemic ketamine and intranasal (IN) esketamine have demonstrated rapid antidepressant effects in treatment-resistant depression (TRD). This systematic review aims to evaluate the efficacy and safety of ketamine and esketamine at various dosages for depression. We included randomized controlled trials (RCTs) with parallel group dose comparison of ketamine and esketamine for...

DOI: 10.1016/j.jad.2024.03.137 Full text Major depressive disorder Clinical trials Dose escalation Intranasal esketamine +5

Number needed to treat (NNT) for ketamine and esketamine in adults with treatment-resistant depression: A systematic review and meta-analysis.

Journal of Affective Disorders July 1, 2024 Cameron N Calder, Angela T H Kwan, Kayla M Teopiz et al. 31 citations

Ketamine has been established as efficacious in adults living with Treatment-resistant Depression (TRD). Toward providing a quantifiable estimate of the clinical meaningfulness of the therapeutic benefit of ketamine, herein, we conduct a systematic review that aims to report the Number Needed to Treat (NNT) and the Number Needed to Harm (NNH). This systematic review searched Embase,...

DOI: 10.1016/j.jad.2024.04.039 Full text Esketamine Treatment-resistant depression Response Treatment resistant depression +4

Efficacy and safety of peri-partum Esketamine for prevention of post-partum depression in women undergoing caesarian section: A meta-analysis and systematic review of randomized controlled trials.

Asian Journal of Psychiatry July 1, 2024 Muhammad Anas Nayyer, Suchna Meeral Khan, Mohammad Umer et al. 14 citations

Postpartum depression (PPD) is a psychiatric condition affecting women post-childbirth. Medication combined with psychotherapy, is the current protocol for its treatment. A meta-analysis was conducted using RevMan 5.4 to explore the efficacy and safety of peri-partum administration of esketamine for preventing PPD. After searching several databases to retrieve the relevant RCTs, seven were...

DOI: 10.1016/j.ajp.2024.104090 Full text Esketamine Meta-analysis Postnatal depression Postpartum depression +1